Skip to main content

DRDO's 2-DG Gets DCGI Approval | INMAS develops anti-covid therapeutic application of 2-deoxy-D-glucose drug

Image
By

 DRDO's 2-DG Gets DCGI Approval | INMAS Develops Anti-Covid Therapeutic Application of 2-Deoxy-D-Glucose Drug


DRDO's anti-Covid drug 2-DG

The anti-COVID-19 therapeutic has been developed by DRDO scientists at the Institute of Nuclear Medicine and Allied Sciences (INMAS).

The Drugs Controller General of India (DCGI), a body responsible for approval of licences of drugs in India, has approved the anti-COVID-19 therapeutic developed by Defence Ministry's  Defence Research and Development Organisation (DRDO). The drug, which received the emergency use authorisation on May 1, is called 2-deoxy-D-glucose (2-DG). According to a press release by the Defence Ministry, clinical trials of 2-DG have demonstrated that it helps in faster recovery of patients severely ill with the COVID-19 disease. The drug helps in faster recovery of hospitalised patients by reducing their dependency on oxygen, which can come in handy in these trying times when the country is suffering from an acute shortage of oxygen concentrators. 

Know everything about DRDO's 2-DG drug

The anti-COVID-19 therapeutic has been developed by DRDO scientists at the Institute of Nuclear Medicine and Allied Sciences (INMAS). The drug has been developed in collaboration between DRDO and Dr Reddy’s Laboratories (DRL) in Hyderabad. The drug was ready for clinical trials in April last year after DRDO and INMAS scientists conducted experiments inside the lab and found 2-DG to be safe and effective against the SARS-CoV-2 virus.

Based on the results from the lab experiment, DCGI permitted DRDO to conduct Phase-II clinical trials of the drug. The trials showed 2-DG was effective against the COVID-19 virus and demonstrated signs of recovery in patients. Following the successful Phase-II trials between May and October 2020, the drug was tested again in Phase-IIa and Phase-IIb trials, which were conducted at six and 11 hospitals respectively. Overall the Phase-II trials were conducted on 110 patients. 

The DRDO received approval to conduct Phase-III trials of the drug by DCGI in November 2020. The Phase-II trials were conducted between December 2020-March 2021 at 27 hospitals across India, including in Delhi, Uttar Pradesh, West Bengal, Maharashtra, Gujarat, Tamil Nadu, Telangana, Karnataka, etc. The Phase-III trials were conducted on 220 patients. The results showed faster recovery in patients who took the drug as compared to those who followed just the Standard of Care (SoC). The use of oxygen in patients who took 2-DG declined significantly. 

How to take the drug?

2-DG comes in powder form, which the infected patients can take orally by mixing up the drug in water. The drug, which is akin to a glucose mix, is easy to manufacture and store, which makes it critical at a time when many people are dying because of the lack of oxygen infrastructure for supply and transportation in India. 



New Source : https://www.republicworld.com/india-news/general-news/drdos-2-dg-gets-dcgi-approval-heres-all-you-need-to-know-about-the-anti-covid-19-drug.html


Comments

Post a Comment

Popular posts from this blog

The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age

By
The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age   The field of regenerative medicine reached a remarkable milestone recently when four women regained full sexual function after the successful implantation of lab-grown vaginas created from their own cells. The women, aged thirteen to eighteen, were born with a rare medical condition called Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) which left them with an abnormal or missing vagina. Each woman underwent a newly engineered procedure that involved taking samples of the patient's own cells and growing them into tissue. This tissue was then placed on a scaffold that was hand-sewn with collagen-like fibers and uniquely shaped to fit each woman’s vaginal cavity. Once the organ fully matured, it was implanted into a canal in each woman’s pelvis, along with the hand-sewn scaffolding. Within six months, the biodegradable scaffolding dissolved and, in each of the four women, the lab-grown vaginas began fun...
Post a Comment
Read more

Gene Therapy for Cancer: A Promising Hope on the Horizon

By
 Gene therapy, a revolutionary approach in modern medicine, holds immense potential for treating cancer by directly altering a patient's genetic makeup to fight the disease. While still in its early stages, it has shown remarkable promise in clinical trials, offering hope for patients with previously untreatable forms of cancer. How does Gene Therapy work for Cancer? Cancer arises from genetic mutations that cause cells to grow and divide uncontrollably. Gene therapy aims to correct these mutations or introduce new genes that can suppress cancer growth. This can be achieved through various methods, including: Replacing faulty genes: Viral vectors are used to deliver healthy copies of genes to cancer cells, replacing the non-functional ones. Silencing cancer-causing genes: Gene therapy can be used to switch off genes that promote cancer cell growth. Introducing genes for immune system activation: Certain genes can be introduced to boost the immune system's ability to recognize a...
Post a Comment
Read more

Black fungus detected in Covid-19 survivors, 8 lose eyesight in Surat | MUCORMYCOSIS

By
 Black fungus detected in Covid-19 survivors, 8 lose eyesight in Surat | MUCORMYCOSIS At least 40 cases of mucormycosis, also known as black fungus, have been reported from Surat in Gujarat among those who have recovered from Covid-19. Of the 40, eight have lost their eyesight. What is this infection and who is more vulnerable? Cases of mucormycosis, commonly known as black fungus, have been reported from Gujarat among those who have recovered from Covid-19. The number of such cases has increased as Gujarat sees an exponential rise in coronavirus infections. At least eight persons were reported to have lost their eyesight in Surat due to mucormycosis (MM) after recovering from Covid-19. They had to be admitted to hospitals for the sudden loss of vision. In the past 15 days, Surat has reported at least 40 cases of mucormycosis or black fungus including eight who have lost their eyesight. The infection, triggered by Covid-19, is treatable but if left untreated or if the treatment is ...
Post a Comment
Read more